Spinal cord injury therapies in humans: An overview of current clinical trials and their potential effects on intrinsic CNS macrophages

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 4, 2011, Pages 505-518

  Gensel, John C ^a   Donnelly, Dustin J ^a   Popovich, Phillip G ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Macrophage; microglia; neuroinflammation; neurotrauma; spinal cord injury

Indexed keywords

ATI 355; BLOCKING AGENT; CETHRIN; CHONDROITIN ABC LYASE; GSK 249320; LITHIUM; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NOGO A ANTIBODY; UNCLASSIFIED DRUG;

AUTOLOGOUS STEM CELL TRANSPLANTATION; DRUG EFFICACY; DRUG SAFETY; EMBRYONAL TISSUE; HEMATOPOIETIC STEM CELL; HUMAN; MACROPHAGE; MACROPHAGE ACTIVATION; NERVE FIBER REGENERATION; NEUROPROTECTION; NONHUMAN; REVIEW; SPINAL CORD INJURY; UMBILICAL CORD BLOOD;

CELL TRANSPLANTATION; CLINICAL TRIALS AS TOPIC; HUMANS; MACROPHAGE ACTIVATION; MACROPHAGES; NEUROPROTECTIVE AGENTS; SPINAL CORD; SPINAL CORD INJURIES; SPINAL CORD REGENERATION; WOUND HEALING;

EID: 79952663518     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2011.553605     Document Type: Review

References (164)

1. Donnelly DJ, Popovich PG. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp Neurol 2008;209:378-88 (Pubitemid 351181428)
2. Fleming JC, Norenberg MD, Ramsay DA, et al. The cellular inflammatory response in human spinal cords after injury. Brain 2006;129:3249-69 (Pubitemid 44871440)
3. Batchelor PE, Porritt MJ, Martinello P, et al. Macrophages and microglia produce local trophic gradients that stimulate axonal sprouting toward but not beyond the wound edge. Mol Cell Neurosci 2002;21:436-53 (Pubitemid 36062730)
4. Benowitz L, Yin YQ. Rewiring the injured CNS: lessons from the optic nerve. Exp Neurol 2008;209:389-98 (Pubitemid 351174128)
5. Bouhy D, Malgrange B, Multon S, et al. Delayed GM-CSF treatment stimulates axonal regeneration and functional recovery in paraplegic rats via an increased BDNF expression by endogenous macrophages. Faseb J 2006;20:1239-41
6. Yin YQ, Henzl MT, Lorber B, et al. Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells. Nat Neurosci 2006;9:843-52
7. Yin YQ, Cui Q, Li YM, et al. Macrophage-derived factors stimulate optic nerve regeneration. J Neurosci 2003;23:2284-93 (Pubitemid 36368916)
8. Calvo CF, Amigou E, Desaymard C, Glowinski J. A pro- and an anti-inflammatory cytokine are synthetised in distinct brain macrophage cells during innate activation. J Neuroimmunol 2008;170:21-30 (Pubitemid 41740904)
9. Giulian D, Vaca K, Corpuz M. Brain glia release factors with opposing actions upon neuronal survival. J Neurosci 1993;13:29-37 (Pubitemid 23028725)
10. Li L, Lu J, Tay SSW, et al. The function of microglia, either neuroprotection or neurotoxicity, is determined by the equilibrium among factors released from activated microglia in vitro. Brain Res 2007;1159:8-17 (Pubitemid 47058024)
11. Pineau I, Lacroix S. Proinflammatory cytokine synthesis in the injured mouse spinal cord: Multiphasic expression pattern and identification of the cell types involved. J Comp Neurol 2007;500:267-85 (Pubitemid 44937122)
12. Gensel JC, Nakamura S, Guan Z, et al. Macrophages promote axon regeneration with concurrent neurotoxicity. J Neurosci 2009;29:3956-68
13. Kigerl KA, Gensel JC, Ankeny DP, et al. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 2009;29:13435-44
14. Stout RD, Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol 2004;76:509-13 (Pubitemid 39129080)
15. Stout RD, Jiang C, Matta B, et al. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005;175(1):342-49 (Pubitemid 40884337)
16. Tetzlaff W, Okon EB, Karimi-Abdolrezaee S, et al. A systematic review of cellular transplantation therapies for spinal cord injury. J Neurotrauma 2010 [Epub ahead of print]
17. Kwon BK, Okon EB, Hillyer J, et al. A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury. J Neurotrauma 2010 [Epub ahead of print]
18. Kwon BK, Okon EB, Plunet W, et al. A systematic review of directly applied biologic therapies for acute spinal cord injury. J Neurotrauma 2010 [Epub ahead of print]
19. Hawryluk GWJ, Rowland J, Kwon BK, Fehlings MG. Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury. Neurosurgical Focus 2008;25(5):E14
20. Short DJ, El Masry WS, Jones PW. High dose methylprednisolone in the management of acute spinal cord injury - a systematic review from a clinical perspective. Spinal Cord 2000;38:273-86 (Pubitemid 30307193)
21. Hall ED, Springer JE. Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx 2004;1:80-100 (Pubitemid 46589342)
22. Elewa HF, Hilali H, Hess DC, et al. Minocycline for short-term neuroprotection. Pharmacotherapy 2006;26:515-21
23. Pinzon A, Marcillo A, Quintana A, et al. A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model. Brain Res 2008;1243:146-51
24. Lee JH, Tigchelaar S, Liu J, et al. Lack of neuroprotective effects of simvastatin and minocycline in a model of cervical spinal cord injury. Exp Neurol 2010;225:219-30
25. Minocycline and Perfusion Pressure Augmentation in Acute Spinal Cord Injury. Bethesda, MD: clinicaltrials.gov, 2007. Available from: . gov/ct2/show/NCT00559494? term=NCT00559494&rank=1 [Last accessed 19 January 2011]
26. Matis GK, Birbilis TA. Erythropoietin in spinal cord injury. Eur Spine J 2009;18:314-23
27. Gorio A, Gokmen N, Erbayraktar S, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 2002;99:9450-5 (Pubitemid 34764634)
28. Guizar-Sahagun G, Rodriguez-Balderas CA, Franco-Bourland RE, et al. Lack of neuroprotection with pharmacological pretreatment in a paradigm for anticipated spinal cord lesions. Spinal Cord 2009;47:156-60
29. Mann C, Lee JH, Liu J, et al. Delayed treatment of spinal cord injury with erythropoietin or darbepoetin - a lack of neuroprotective efficacy in a contusion model of cord injury. Exp Neurol 2008;211:34-40
30. Pinzon A, Marcillo A, Pabon D, et al. A re-assessment of erythropoietin as a neuroprotective agent following rat spinal cord compression or contusion injury. Exp Neurol 2008;213:129-36
31. Evaluation of Tolerability and Efficacy of Erythropoietin (EPO) Treatment in Spinal Shock: Comparative Study Versus Methylprednisolone (MP). Bethesda, MD: clinicaltrials.gov, 2007. Available from: NCT00561067?term=NCT00561067& rank=1[Last accessed 19 January 2011]
32. Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal-cord trauma with emphasis on vascular mechanisms. J Neurosurg 1991;75:15-26
33. Teng YD, Wrathall JR. Local blockade of sodium channels by tetrodotoxin ameliorates tissue loss and long-term functional deficits resulting from experimental spinal cord injury. J Neurosci 1997;17:4359-66 (Pubitemid 27220626)
34. Stys PK. Sodium channel blockers as neuroprotectants in neuroinflammatory disease: a double-edged sword. Ann Neurol 2007;62:3-5 (Pubitemid 47235273)
35. Ransom BR, Fern R. Does astrocytic glycogen benefit axon function and survival in CNS white matter during glucose deprivation? Glia 1997;21:134-41 (Pubitemid 27389649)
36. 2+ exchanger. J Neurosci 1996;16(2):545-52
37. Ates O, Cayli SR, Gurses I, et al. Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury. J Clin Neurosci 2007;14:658-65 (Pubitemid 46783492)
38. Schwartz G, Fehlings MG. Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole. J Neurosurg 2001;94:245-56 (Pubitemid 32786052)
39. HP184 in Chronic Spinal Cord Injury Subjects. Bethesda, MD: clinicaltrials. gov, 2004. Available from: http:// clinicaltrials.gov/ct2/show/ NCT00093275?term=NCT00093275& rank=1 [Last accessed 19 January 2011]
40. HP184 Trial-Discussion. Paralysis Resource Center, Princeton, NJ: Inspire, 2007. Available from: . com/groups/paralysis-resource-center/ discussion/hp184-trial/ [Last accessed 25 January 2011]
41. Safety of Riluzole in Patients With Acute Spinal Cord Injury. Bethesda, MD: clinicaltrials.gov, 2009. Available from: ct2/show/NCT00876889? term=NCT00876889&rank=1 [Last accessed 19 January 2011]
42. Dietrich WD, Bramlett HM. The evidence for hypothermia as a neuroprotectant in traumatic brain injury. Neurotherapeutics 2010;7:43-50
43. Levi AD, Casella G, Green BA, et al. Clinical outcomes using modest intravascular hypothermia after acute cervical spinal cord injury. Neurosurgery 2010;66:670-7
44. Levi AD, Green BA, Wang MY, et al. Clinical application of modest hypothermia after spinal cord injury. J Neurotrauma 2009;26:407-15
45. Clinical Trials Initiative. The Miami Project Cure for Paralysis, Miami, FL: University of Miami, 2010. Available from: . miami.edu/Page.aspx?pid=339 [Last accessed 19 January 2011]
46. Popovich PG, Guan Z, Wei P, et al. Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. Exp Neurol 1999;158:351-65 (Pubitemid 29382826)
47. Eng LF, Lee YL. Response of chemokine antagonists to inflammation in injured spinal cord. Neurochem Res 2003;28:95-100 (Pubitemid 36173230)
48. Gris D, Marsh DR, Oatway MA, et al. Transient blockade of the CD11d/CD18 integrin reduces secondary damage after spinal cord injury, improving sensory, autonomic, and motor function. J Neurosci 2004;24:4043-51 (Pubitemid 38544230)
49. Blight AR. Effects of silica on the outcome from experimental spinal-injury - implication of macrophages in secondary tissue damage. Neuroscience 1994;60:263-73 (Pubitemid 24147624)
50. Giulian D, Robertson C. Inhibition of mononuclear phagocytes reduces ischemic injury in the spinal cord. Ann Neurol 1990;27:33-42 (Pubitemid 20031356)
51. Iannotti CA, Clark M, Horn KP, et al. A combination immunomodulatory treatment promotes neuroprotection and locomotor recovery after contusion SCI. Exp Neurol 2010 [Epub ahead of print]
52. Horn KP, Busch SA, Hawthorne AL, et al. Another barrier to regeneration in the CNS: Activated macrophages induce extensive retraction of dystrophic axons through direct physical interactions. J Neurosci 2008;28:9330-41
53. Bao F, Dekaban GA, Weaver LC. Anti-CD11d antibody treatment reduces free radical formation and cell death in the injured spinal cord of rats. J Neurochem 2005;94:1361-73 (Pubitemid 41232591)
54. Ditor DS, Bao F, Chen YH, et al. A therapeutic time window for anti-CD11d monoclonal antibody treatment yielding reduced secondary tissue damage and enhanced behavioral recovery following severe spinal cord injury. J Neurosurg-Spine 2006;5:343-52 (Pubitemid 47325374)
55. Effects of Continuous Combined Hormone Replacement Therapy and Clodronate on Bone Mineral Density (BMD) in Osteoporotic Women. Bethesda, MD: clinicaltrials.gov, 2009. Available from: . gov/ct/show/NCT00877097? term=NCT00877097&rank=1 [Last accessed 19 January 2011]
56. Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer. Bethesda, MD: clinicaltrials.gov, 2009. Available from: NCT00009945?term=NCT00009945& rank=1 [Last accessed 19 January 2011]
57. A Study of Efalizumab in Patients With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies. Bethesda, MD: clinicaltrials.gov, 2005. Available from: NCT00249808?term=NCT00249808& rank=1 [Last accessed 19 January 2011]
58. Bartholdi D, Schwab ME. Methylprednisolone inhibits early inflammatory processes but not ischemic cell death after experimental spinal cord lesion in the rat. Brain Res 1995;672(1-2):177-86
59. Xu J, Kim GM, Ahmed SH, et al. Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury. The Journal of Neuroscience: the official journal of the Society for Neuroscience 2001;21:92-7 (Pubitemid 32098730)
60. Qian T, Campagnolo D, Kirshblum S. High-dose methylprednisolone may do more harm for spinal cord injury. Med Hypotheses 2000;55:452-3
61. Kubeck JP, Merola A, Mathur S, et al. End organ effects of high-dose human equivalent methylprednisolone in a spinal cord injury rat model. Spine (Phila Pa 1976) 2006;31(3):257-61 (Pubitemid 43214764)
62. Matsumoto T, Tamaki T, Kawakami M, et al. Early complications of high-dose methylprednisolone sodium succinate treatment in the follow-up of acute cervical spinal cord injury. Spine (Phila Pa 1976) 2001;26:426-30 (Pubitemid 32184858)
63. Kim YT, Caldwell JM, Bellamkonda RV. Nanoppages-mediated local delivery of Methylprednisolone after spinal cord injury. Biomaterials 2009;30:2582-90
64. Stirling DP, Khodarahmi K, Liu J, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 2004;24:2182-90 (Pubitemid 38314550)
65. Festoff BW, Ameenuddin S, Arnold PM, et al. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem 2006;97:1314-26 (Pubitemid 43725571)
66. Lee SM, Yune TY, Kim SJ, et al. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 2003;20:1017-27 (Pubitemid 37288561)
67. Teng YD, Choi H, Onario RC, et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci USA 2004;101:3071-6 (Pubitemid 38327736)
68. Wells JE, Hurlbert RJ, Fehlings MG, Yong VW. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 2003;126:1628-37 (Pubitemid 36834939)
69. Yune TY, Lee JY, Jung GY, et al. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J Neurosci 2007;27:7751-61 (Pubitemid 47093808)
70. Tikka T, Fiebich BL, Goldsteins G, et al. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 2001;21:2580-8 (Pubitemid 32298200)
71. Ha KY, Kim YH. Neuroprotective effect of moderate epidural hypothermia after spinal cord injury in rats. Spine 2008;33:2059-65
72. Morino T, Ogata T, Takeba J, Yamamoto H. Microglia inhibition is a target of mild hypothermic treatment after the spinal cord injury. Spinal Cord 2008;46:425-31 (Pubitemid 351793816)
73. Chatzipanteli K, Yanagawa Y, Marcillo AE, et al. Posttraumatic hypothermia reduces polymorphonuclear leukocyte accumulation following spinal cord injury in rats. J Neurotrauma 2000;17:321-32 (Pubitemid 30205484)
74. Roselli F, Livrea P, Jirillo E. Voltage-gated sodium channel blockers as immunomodulators. Recent Patents CNS Drug Discov 2006;1:83-91
75. Craner MJ, Damarjian TG, Liu S, et al. Sodium channels contribute to microglia/ macrophage activation and function in EAE and MS. Glia 2005;49:220-9 (Pubitemid 40188501)
76. Sandvig A, Berry M, Barrett LB, et al. Myelin-, reactive glia-, and scar-derived CNS axon growth inhibitors: expression, receptor signaling, and correlation with axon regeneration. Glia 2004;46:225-51 (Pubitemid 38679204)
77. Nash M, Pribiag H, Fournier AE, Jacobson C. Central nervous system regeneration inhibitors and their intracellular substrates. Mol Neurobiol 2009;40:224-35
78. Gonzenbach RR, Schwab ME. Disinhibition of neurite growth to repair the injured adult CNS: Focusing on Nogo. Cellular and Molecular Life Sciences 2008;65:161-76
79. Morgenstern DA, Asher RA, Fawcett JW. Chondroitin sulphate proteoglycans in the CNS injury response. Prog Brain Res 2002;137:313-32 (Pubitemid 35460952)
80. Domeniconi M, Cao ZU, Spencer T, et al. Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron 2002;35:283-90 (Pubitemid 34876731)
81. Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in PatientsWith Acute SCI. Bethesda,MD: clinicaltrials.gov, 2006. Available from: ct/show/NCT00406016?term= NCT00406016&rank=1 [Last accessed 19 January 2011]
82. Anti-MAG First Administration to Human. Bethesda, MD: clinicaltrials.gov, 2008. Available from: . gov/ct/show/NCT00622609? term=NCT00622609&rank=1 [Last accessed 19 January 2011]
83. Result Summaries: GSK249320. GlaxoSmithKline, Brentford, Middlesex, UK: 2009. Available from: . com/files/20887.pdf [Last accessed 19 January 2011]
84. Safety Escalating Repeat IV, in Stroke Patients (MAG111539). Bethesda, MD: clinicaltrials.gov, 2009. Available from: NCT00833989?term=NCT00833989& rank=1 [Last accessed 19 January 2011]
85. Crespo D, Asher RA, Lin R, et al. How does chondroitinase promote functional recovery in the damaged CNS? Exp Neurol 2007;206:159-71 (Pubitemid 47094767)
86. Houle JD, Tom VJ, Mayes D, et al. Combining an autologous peripheral nervous system bridge and matrix modification by chondroitinase allows robust, functional regeneration beyond a hemisection lesion of the adult rat spinal cord. J Neurosci 2006;26:7405-15 (Pubitemid 44315209)
87. Karimi-Abdolrezaee S, Eftekharpour E, Wang J, et al. Synergistic effects of transplanted adult neural stem/progenitor cells, chondroitinase, and growth factors promote functional repair and plasticity of the chronically injured spinal cord. J Neurosci 2010;30:1657-76
88. Lee H, McKeon RJ, Bellamkonda RV. Sustained delivery of thermostabilized chABC enhances axonal sprouting and functional recovery after spinal cord injury. Proc Natl Acad Sci USA 2009;107:3340-5
89. Steinmetz MP, Horn KP, Tom VJ, et al. Chronic enhancement of the intrinsic growth capacity of sensory neurons combined with the degradation of inhibitory proteoglycans allows functional regeneration of sensory axons through the dorsal root entry zone in the mammalian spinal cord. J Neurosci 2005;25:8066-76 (Pubitemid 41254410)
90. Tom VJ, Sandrow-Feinberg HR, Miller K, et al. Combining peripheral nerve grafts and chondroitinase promotes functional axonal regeneration in the chronically injured spinal cord. J Neurosci 2009;29:14881-90
91. Yick LW, So KF, Cheung PT, Wu WT. Lithium chloride reinforces the regeneration-promoting effect of chondroitinase ABC on rubrospinal neurons after spinal cord injury. J Neurotrauma 2004;21:932-43
92. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Safety results of two Phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005;140:585-97
93. Lord-Fontaine S, Yang F, Diep Q, et al. Local inhibition of Rho signaling by cell-permeable recombinant protein BA-210 prevents secondary damage and promotes functional recovery following acute spinal cord injury. J Neurotrauma 2008;25:1309-22
94. Dill J, Wang H, Zhou F, Li S. Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the CNS. J Neurosci 2008;28:8914-28
95. A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries. Bethesda, MD: clinicaltrials.gov, 2007. Available from: NCT00500812?term=NCT00500812& rank=1 [Last accessed 19 January 2011]
96. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin (R) Clinical Trial in Acute Spinal Cord Injury. Alseres Pharmaceuticals, Hoptkinton, MA: PR Newswire, 2008. Available from: http:// files.shareholder.com/downloads/BLSI/ 0x0x195293/344f8fc9-9f34- 4e6b-a72d-184885f8d37b/ ALSE-News-2008-5-12- General-Releases.pdf [Last accessed 19 January 2011]
97. Safety and Efficacy of Cethrin® in Adult Subjects With Acute Cervical Spinal Cord Injury. Bethesda, MD: clinicaltrials. gov, 2008. Available from: http:// clinicaltrials.gov/ct/show/ NCT00610337?term=NCT00610337& rank=1 [Last accessed 19 January 2011]
98. Form 10-K for Alseres Pharmaceuticals Inc /DE. Yahoo! Finance, Sunnyvale, CA: Yahoo! News Network, 2010. Available from: . com/e/100331/alse.pk10-k.html [Last accessed 19 January 2011]
99. Seira O, Gavin R, Gil V, et al. Neurites regrowth of cortical neurons by GSK3beta inhibition independently of Nogo receptor 1. J Neurochem 2010;113:1644-58
100. Alabed YZ, Pool M, Tone SO, et al. GSK3beta regulates myelin-dependent axon outgrowth inhibition through CRMP4. J Neurosci 2010;30:5635-43
101. Safety and Pharmacokinetics Study of Oral Lithium in Patients With Chronic Spinal Cord Injury. Bethesda, MD: clinicaltrials.gov, 2008. Available from: NCT00431171?term=NCT00431171& rank=1 [Last accessed 19 January 2011]
102. Efficacy and Safety of Lithium Carbonate in the Treatment of Chronic Spinal Cord Injuries. Bethesda, MD: clinicaltrials.gov, 2008. Available from: NCT00750061?term=NCT00750061& rank=1 [Last accessed 19 January 2011]
103. Su HX, Chu TH, Wu WT. Lithium enhances proliferation and neuronal differentiation of neural progenitor cells in vitro and after transplantation into the adult rat spinal cord. Exp Neurol 2007;206:296-307
104. Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord. Bethesda, MD: clinicaltrials.gov, 2010. Available from: NCT01046786?term=NCT01046786& rank=1 [Last accessed 19 January 2011]
105. Zhu Z, Ni B, Yin G, et al. NgR expression in macrophages promotes nerve regeneration after spinal cord injury in rats. Archives of Orthopaedic and Trauma Surgery 2010;130:945-51
106. David S, Fry EJ, LUpez-Vales R. Novel roles for Nogo receptor in inflammation and disease. Trends Neurosci 2008;31:221-6
107. Pool M, Niino M, Rambaldi I, et al. Myelin regulates immune cell adhesion and motility. Exp Neurol 2009;217:371-7
108. David S, Bouchard C, Tsatas O, Giftochristos N. Macrophages can modify the nonpermissive nature of the adult mammalian central-nervous-system. Neuron 1990;5:463-9 (Pubitemid 20369582)
109. Rolls A, Shechter R, London A, et al. Two faces of chondroitin sulfate proteoglycan in spinal cord repair: a role in microglia/macrophage activation. Plos Medicine 2008;5:1262-77
110. Ebert S, Schoeberl T, Walczak Y, et al. Chondroitin sulfate disaccharide stimulates microglia to adopt a novel regulatory phenotype. J Leukoc Biol 2008;84:736-40
111. Busch SA, Horn KP, Silver DJ, Silver J. Overcoming macrophage-mediated axonal dieback following CNS injury. J Neurosci 2009;29:9967-76
112. Baptiste DC, Tighe A, Fehlings MG. Spinal cord injury and neural repair: focus on neuroregenerative approaches for spinal cord injury. Expert Opin Investig Drugs 2009;18:663-73
113. Zhao D, Pothoulakis C. Rho GTPases as therapeutic targets for the treatment of inflammatory diseases. Expert Opin Ther Targets 2003;7:583-92 (Pubitemid 37258837)
114. Conrad S, Schluesener HJ, Trautmann K, et al. Prolonged lesional expression of RhoA and RhoB following spinal cord injury. J Comp Neurol 2005;487:166-75 (Pubitemid 40734117)
115. Vallieres N, Berard JL, David S, Lacroix S. Systemic injections of lipopolysaccharide accelerates myelin phagocytosis during Wallerian degeneration in the injured mouse spinal cord. Glia 2006;53:103-13 (Pubitemid 43076217)
116. Beurel E, Michalek SM, Jope RS. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol 2010;31:24-31
117. Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005;6:777-84 (Pubitemid 43090463)
118. Yuskaitis CJ, Jope RS. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal 2009;21:264-73
119. Zhang M, Jin W, Zhou X, et al. Deregulation of Tpl2 and NF-Kb signaling and induction of macrophage apoptosis by the anti-depressant drug lithium. Cell Signal 2009;21:559-66
120. Knoller N, Auerbach G, Fulga V, et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: Phase I study results. J Neurosurg-Spine 2005;3:173-81
121. Kigerl K, Popovich P. Drug evaluation: ProCord - a potential cell-based therapy for spinal cord injury. Idrugs 2006;9:354-60 (Pubitemid 43772975)
122. Schwartz M, Yoles E. Immune-based therapy for spinal cord repair: autologous macrophages and beyond. J Neurotrauma 2006;23:360-70 (Pubitemid 43739276)
123. Autologous Incubated Macrophages for Patients With Complete Spinal Cord Injuries. Bethesda, MD: clinicaltrials.gov, 2003. Available from: . gov/ct2/show/NCT00073853? term=NCT00073853&rank=1 [Last accessed 19 January 2011]
124. Jones LA, Lammertse DP, Charlifue SB, et al. A phase 2 autologous cellular therapy trial in patients with acute, complete spinal cord injury: pragmatics, recruitment, and demographics. Spinal cord : the official journal of the International Medical Society of Paraplegia 2010;48:798-807
125. Radtke C, Sasaki M, Lankford KL, et al. Potential of olfactory ensheathing cells for cell-based therapy in spinal cord injury. J Rehabil Res Dev 2008;45:141-51
126. Feron F, Perry C, Cochrane J, et al. Autologous olfactory ensheathing cell transplantation in human spinal cord injury. BrainJ Neurol 2005;128:2951-60 (Pubitemid 41746648)
127. Lima C, Pratas-Vital J, Escada P, et al. Olfactory mucosa autografts in human spinal cord injury: a pilot clinical study. J Spinal Cord Med 2006;29:191-6
128. Transplantation of Autologous Olfactory Ensheathing Cells in Complete Human Spinal Cord Injury. Bethesda, MD: clinicaltrials.gov, 2010. Available from: NCT01231893?term=NCT01231893& rank=1 [Last accessed 19 January 2011]
129. Zhang N, Wimmer J, Qian SJ, Chen WS. Stem cells: current approach and future prospects in spinal cord injury repair. Anat Rec Adv Integr Anat Evol Biol 2010;293:519-30
130. Kumar AA, Kumar SR, Narayanan R, et al. Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: a Phase I/II clinical safety and primary efficacy data. Exp Clin Transplant 2009;7:241-8
131. Cell Transplant in Spinal Cord Injury Patients. Bethesda, MD: clinicaltrials.gov, 2008. Available from: . gov/ct2/show/NCT00816803? term=NCT00816803&rank=1 [Last accessed 19 January 2011]
132. Amr SM, Gouda A, Koptan WT, et al. Mesenchymal stem cell derived neural stem cell-like cell transplantation of the spinal cord with or without sural nerve grafting or a chitosan-laminin scaffold; clinical experience based on eighteen cases. Frontiers in Neuroscience 2009;Conference Abstract: 3rd Mediterranean Conference of Neuroscience. doi: 10.3389/conf. neuro.01.2009.16.091
133. Treatment for Acute Spinal Cord Injury. Bethesda, MD: clinicaltrials.gov, 2008. Available from: . gov/ct2/show/NCT00695149? term=NCT00695149&rank=1 [Last accessed 19 January 2011]
134. Saito F, Nakatani T, Iwase M, et al. Spinal cord injury treatment with intrathecal autologous bone marrow stromal cell transplantation: the first clinical trial case report. J Trauma Inj Infect Crit Care 2008;64:53-9
135. Transfer of Bone Marrow Derived Stem Cells for the Treatment of Spinal Cord Injury. Bethesda, MD: clinicaltrials.gov, 2010. Available from: . gov/ct2/show/NCT01162915? term=NCT01162915&rank=1 [Last accessed 19 January 2011]
136. Safety and Efficacy of Autologous Bone Marrow Stem Cells in Treating Spinal Cord Injury (ABMST-SCI). Bethesda, MD: clinicaltrials.gov, 2010. Available from: NCT01186679?term=NCT01186679& rank=1 [Last accessed 19 January 2011]
137. Stem Cell Therapy. International Stem Cell Services Limited, Karnataka, India: 2010. Available from: . internationalstemcellservices.com/ stem-cell-therapy.html [Last accessed 19 Januaryr 2011]
138. Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord. Bethesda, MD: clinicaltrials.gov, 2010. Available from: NCT01046786? term=NCT01046786&rank=1 [Last accessed 19 Januaryr 2011]
139. Cyranoski D. Chinese network to start trials of spinal surgery. Nature 2007;446:476-7 (Pubitemid 46514701)
140. Kang KS, Kim SW, Oh YH, et al. A 37-year-old spinal cord-injured female patient, transplanted of multipotent stem cells from human UC blood, withimproved sensory perception and mobility, both functionally and morphologically: a case study. Cytotherapy 2005;7:368-73 (Pubitemid 41535842)
141. Faulkner J, Keirstead HS. Human embryonic stem cell-derived oligodendrocyte progenitors for the treatment of spinal cord injury. Transplant immunol 2005;15:131-42 (Pubitemid 43075333)
142. Safety Study of GRNOPC1 in Spinal Cord Injury. Bethesda, MD: clinicaltrials. gov, 2010. Available from: http:// clinicaltrials.gov/ct2/show/ NCT01217008?term=NCT01217008& rank=1 [Last accessed 19 January 2011]
143. Deda H, Inci MC, Kurekci AE, et al. Treatment of chronic spinal cord injured patients with autologous bone marrow-derived hematopoietic stem cell transplantation: 1-year follow-up. Cytotherapy 2008;10:565-74
144. Pal R, Venkataramana NK, Jaan M, et al. Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/ paraplegia: a pilot clinical study. Cytotherapy 2009;11:897-911
145. Moviglia GA, Vina RF, Brizuela JA, et al. Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patients. Cytotherapy 2006;8:202-9 (Pubitemid 43947786)
146. Qiu J. China Spinal Cord Injury Network: changes from within. Lancet Neurol 2009;8:606-7
147. Tator CH. Review of treatment trials in human spinal cord injury: Issues, difficulties, and recommendations. Neurosurgery 2006;59:957-82
148. Dobkin BH, Curt A, Guest J. Cellular transplants in China: observational study from the largest human experiment in chronic spinal cord injury. Neurorehabil Neural Repair 2006;20:5-13 (Pubitemid 43214453)
149. Cyranoski D. Patients warned about unproven spinal surgery. Nature 2006;440:850-1
150. Cyranoski D. Fetal-cell therapy: paper chase. Nature 2005;437:810-11
151. Abrams MB, Dominguez C, Pernold K, et al. Multipotent mesenchymal stromal cells attenuate chronic inflammation and injury-induced sensitivity to mechanical stimuli in experimental spinal cord injury. Restor Neurol Neurosci 2009;27:307-21
152. Chen CT, Foo NH, Liu WS, Chen SH. Infusion of human umbilical cord blood cells ameliorates hind limb dysfunction in experimental spinal cord injury through anti-inflammatory, vasculogenic and neurotrophic mechanisms. Pediatr Neonatol 2008;49:77-83
153. Yang CC, Shih YH, Ko MH, et al. Transplantation of Human Umbilical Mesenchymal Stem Cells from Whartons Jelly after Complete Transection of the Rat Spinal Cord. PLoS ONE 2008;3(10):e3336
154. Lopez-Vales R, Garcia-Alias G, Fores J, et al. Transplanted olfactory ensheathing cells modulate the inflammatory response in the injured spinal cord.
155. Garbuzova-Davis S, Sanberg CD, Kuzmin-Nichols N, et al. Human umbilical cord blood treatment in a mouse model of ALS: Optimization of cell dose. PLoS ONE 2008;3(6):e2494
156. Nikolic WV, Hou HY, Town T, et al. Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice. Stem Cells Dev 2008;17:423-39 (Pubitemid 351948205)
157. Ohtaki H, Ylostalo JH, Foraker JE, et al. Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/ immune responses. Proc Natl Acad Sci USA 2008;105:14638-43
158. Kim YJ, Park HJ, Lee G, et al. Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action. Glia 2009;57:13-23
159. Maggini J, Mirkin G, Bognanni I, et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS ONE 2010;5(2):e9252
160. Zhou C, Zhang C, Chi S, et al. Effects of human marrow stromal cells on activation of microglial cells and production of inflammatory factors induced by lipopolysaccharide. Brain Res 2009;1269:23-30
161. Bottai D, Cigognini D, Madaschi L, et al. Embryonic stem cells promote motor recovery and affect inflammatory cell infiltration in spinal cord injured mice. Exp Neurol 2010;223:452-63
162. Hill CE, Proschel C, Noble M, et al. Acute transplantation of glial-restricted precursor cells into spinal cord contusion injuries: survival, differentiation, and effects on lesion environment and axonal regeneration. Exp Neurol 2004;190:289-310 (Pubitemid 39504988)
163. Shechter R, London A, Varol C, et al. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. Plos Medicine 2009;6(7):e1000113
164. Pilot Study: The Role of Migration Inhibitory Factor (MIF) in Spinal Cord Injury. Bethesda, MD: clinicaltrials.gov, 2010. Available from: . gov/ct2/show/NCT00919581? term=NCT00919581&rank=1 [Last accessed 19 Januray 2011]